Post-translational regulation of GLT-1 in neurological diseases and its potential as an effective therapeutic target

44Citations
Citations of this article
63Readers
Mendeley users who have this article in their library.

Abstract

Glutamate transporter-1 (GLT-1) is a Na+-dependent transporter that plays a key role in glutamate homeostasis by removing excess glutamate in the central nervous system (CNS). GLT-1 dysregulation occurs in various neurological diseases including Huntington’s disease (HD), Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and epilepsy. Downregulation or dysfunction of GLT-1 has been a common finding across these diseases but how this occurs is still under investigation. This review aims to highlight post-translational regulation of GLT-1 which leads to its downregulation including sumoylation, palmitoylation, nitrosylation, ubiquitination, and subcellular localization. Various therapeutic interventions to restore GLT-1, their proposed mechanism of action and functional effects will be examined as potential treatments to attenuate the neurological symptoms associated with loss or downregulation of GLT-1.

Cite

CITATION STYLE

APA

Peterson, A. R., & Binder, D. K. (2019, July 9). Post-translational regulation of GLT-1 in neurological diseases and its potential as an effective therapeutic target. Frontiers in Molecular Neuroscience. Frontiers Media S.A. https://doi.org/10.3389/fnmol.2019.00164

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free